Global Point-of-Care Testing Market (POCT) was valued at US$ 20.42 billion in 2018 and is anticipated to reach US$ 29.27 billion by 2025 displaying a reasonable CAGR of 5.33% over the forecast period (2019-2025). There have been tremendous advances in point-of-care diagnostics in recent years which are a result of continuous developments in biosensors, microfluidic, bioanalytical platforms, assay formats, lab-on-a-chip technologies, and complementary technologies. The current trend in POCD is inclined strongly towards smart devices equipped with mobile healthcare (mH), which could truly revolutionize personalized healthcare monitoring and management, thereby paving the way for next-generation POCT.
POCT plays a vital role in patient management, as it critically shortens the time-to-treatment, enables the classification of stroke subtypes, and improves the patient’s outcome. A varied range of POC assays has been developed for the quantitative determination of biomarkers by using portable and easy-to-use POC clinical and biochemical analyzers. Therefore, POCT enables the rapid clinical decision-making in the diagnosis of ischemic stroke, which could considerably improve patient outcomes by facilitating treatment and medical intervention at an early stage. In the United States, under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), all clinical laboratory testing including point-of-care testing (POCT) examining is regulated.
The global Point-of-Care Testing market by product type is bifurcated in Blood Glucose Monitoring Test, Pregnancy & Fertility Testing, Infectious Disease Testing, Cardiac Markers, Anticoagulant Management, Others. Blood Glucose Monitoring Test products. The blood glucose testing products dominated the market accounting for 75.1% share in 2018 and is anticipated to maintain its dominance during the forecast period. In hospitals, control of blood glucose (BG) in narrow therapeutic ranges requires appropriate near-patient glucose monitoring techniques that need to be rapid, accurate, and cost-effective. The reference standard remains central laboratory testing (CLT) of plasma glucose.
Request for the sample of the Report browse through –
Near the Patient (NPT) and Over the Counter (OTC) /Patient Self-Testing (PST) is the major segments based on prescription type in the global POCT market. Over the Counter/Patient Self-Testing (OTC/PST) occupied the largest share and is expected to maintain its dominance throughout the forecast period 2019-2025. The PST provides patients the freedom to test their International Normalized Ratio (INR) from anywhere and at any time with quick results which are comparable to those from the laboratory.
Based on end-users, the report segments the global POCT market into Hospitals, Clinics & laboratories, home settings, and others are the major end-users. In 2018, Hospitals were the largest revenue-generating segment for technology. However, the home setting segment is expected to witness the highest CAGR growth of 6.09% during the forecast period 2019-2025 owing to its expanded applications and evolution in the home testing kits. There are tests available to assist with the diagnosis of a wide range of conditions, from sexually transmitted infections and stomach ulcers to Alzheimer’s disease and even cancer. Patients with long-term medical complaints can accurately monitor their conditions using home testing kits, such as diabetics checking their blood glucose levels, however, the people can also buy over-the-counter genetic testing kits depending upon their feasibility and interest.
For a deep-dive analysis of the overall adoption of POCT technology, a detailed analysis was conducted for major regions/countries including North America (US, Canada), Europe (Germany, France, Spain, Italy, UK), Asia-Pacific (China, India, Japan, Australia) and Rest of the world. In 2018, North America dominated the market with ~half the market. However, increasing elderly populations majorly in countries such as Japan and China, Asia-Pacific would emerge as one of the larger markets for the technology in years to come.
For detailed analysis on the prescription available and current and future use of Diagnostic Products in Global Point-of-Care Testing browse through
Roche Diagnostics, Becton, Dickinson and Company, Abbott Laboratories, Inc., Biomérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, Johnson & Johnson, Siemens Healthineers, Sysmex Corporation, and Thermo Fisher Scientific are some of the prominent players operating in the global point-of-care testing market at the global scale. However, owing to the increasing old age population and rising prevalence of age-related disorders, the industry has witnessed the emergence of numerous start-ups operating at the regional/country level.
Global Point-of-Care Testing Market Segmentation
Market Insights, by Product
- Blood Glucose Monitoring Test
- Pregnancy & Fertility Testing
- Infectious Disease Testing
- Cardiac Markers
- Anticoagulant Management
Market Insights, by Prescription
- Near the Patient Testing (NPT)
- Over the Counter (OCT) /Patient Self-Testing (PST)
Market Insights, by End-User
- Clinics & Laboratory
- Home Setting
- Other Health Facilities
Market Insights, by Region
- North America
- United States
- Rest of NA
- United Kingdom
- Rest of Europe
- Rest of APAC
- Rest of World
Top Company Profiles
- Abbott Laboratories
- Becton, Dickinson, and Company
- Biomerieux SA
- Bio-Rad Laboratories
- Danaher Corporation
- Johnson & Johnson
- Roche Holding AG
- Siemens Healthineers AG
- Thermo Fisher Scientific
- Sysmex Corporation
The Global Point-of-Care testing Market can be customized to the country level or any other application. Besides this, UMI understands that you may have your own business need, hence we also provide fully customized solutions to clients. The Global POCT Market can be customized to the country level or any other market segment.
UnivDatos Market Insights (UMI) Latest Research Report –
UnivDatos Market Insights (UMI), is a passionate market research firm and a subsidiary of Universal Data Solutions. Rigorous secondary and primary research on the market is our USP, hence information presented in our reports is based on facts and realistic assumptions. We have worked with 200+ global clients, including some of the fortune 500 companies. Our clientele praises us for quality of insights, In-depth analysis, custom research abilities and detailed market segmentation.